 PALO ALTO, Calif., Aug. 5, 2021 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq: EIGR, a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its second quarter 2021 financial results and provided a business update. 